Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06319963

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Led by Theravectys S.A. · Updated on 2026-02-02

72

Participants Needed

4

Research Sites

120 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.

CONDITIONS

Official Title

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
  • ECOG performance status of 0 or 1
  • Adequate hepatic, renal, pulmonary, and bone marrow/hematological function
Not Eligible

You will not qualify if you...

  • Seropositivity for HIV
  • Active hepatitis C virus (HCV) infection
  • Active hepatitis B (HBV) infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Florida Cancer Specialists (from Sarah Canon research Institute)

Orlando, Florida, United States, 32827

Actively Recruiting

2

Tampa General Hospital

Tampa, Florida, United States, 33606

Actively Recruiting

3

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

4

Oklahoma Cancer Specialists and Research Institute, LLC

Tulsa, Oklahoma, United States, 74146

Actively Recruiting

Loading map...

Research Team

D

Daniel Loera

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here